Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch Automation brings you the latest, most pertinent content at record speed and with ...

We recently compiled a list of the 7 Stocks on Jim Cramer’s Radar. In this article, we are going to take a look at where Eli ...

We recently compiled a list of the 12 Safest Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other ...

Each one of the 26 respondents who brought documentary features to Sundance in 2025 has their own fascinating set of ...

The U.S. telecom major is planning to exit a majority of its copper network operations by 2029 as customers shift to newer ...

Donkey Kong Country Returns HD is a passable remaster of an amazing platformer – more modern improvements and a larger graphical update would have been nice, but this is still one of the ...

In a report released today, Akash Tewari from Jefferies maintained a Buy rating on Eli Lilly & Co (LLY – Research Report), with a price target of $996.00. The company’s shares closed yesterday ...

Jan 15 (Reuters) - Eli Lilly (LLY.N), opens new tab said on Wednesday the U.S. health regulator has approved its drug to treat adults with moderate-to-severe Crohn's disease, a type of chronic ...

Eli Lilly and Company (NYSE:LLY) announced on Tuesday that the pharmaceuticals company expects Q4 2024 revenue to be ~$13.5B. The consensus revenue estimate stands at $13.95B. "While the U.S ...

Lilly anticipates revenue growth contributions in 2025 from new Lilly medicines such as Jaypirca, Ebglyss, Omvoh and Kisunla; approvals of new indications for existing Lilly medicines; launches of ...

((This Jan. 13 story has been corrected to say 'drugmakers will ask,' not 'Eli Lilly has asked' to pause negotiations, after the company clarified, in the headline & paragraph 1)) (Reuters) - ...

(Reuters) - Eli Lilly has asked the U.S. government to pause the new law that allows Medicare to negotiate prices for its costliest prescription drugs, Bloomberg News reported on Monday, citing Lilly ...